(Q34692107)

4 August 2017

0 references

Impact of vitamin D on chronic kidney diseases in non-dialysis patients: a meta-analysis of randomized controlled trials (English)

1 reference

4 August 2017

0 references

0 references

1 reference

1 reference

Lijuan Xu

1

1 reference

4 August 2017

Xuesi Wan

2

1 reference

4 August 2017

Zhimin Huang

3

1 reference

4 August 2017

Fangfang Zeng

4

1 reference

4 August 2017

Guohong Wei

5

1 reference

4 August 2017

Donghong Fang

6

1 reference

4 August 2017

Wanping Deng

7

1 reference

4 August 2017

Yanbing Li

8

1 reference

4 August 2017

language of work or name

English

0 references

publication date

23 April 2013

1 reference

4 August 2017

1 reference

4 August 2017

8

1 reference

4 August 2017

4

1 reference

4 August 2017

e61387

1 reference

Creative Commons Attribution 4.0 International

4 August 2017

start time

23 April 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Hypovitaminosis D in chronic kidney disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Recovery and maintenance of nephrin expression in cultured podocytes and identification of HGF as a repressor of nephrin

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

7 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

Reduced glomerular filtration rate in asymptomatic diabetic patients: predictor of increased risk for cardiac events independent of albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

Prognostic significance of a reduced glomerular filtration rate and interaction with microalbuminuria in resistant hypertension: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

Antiproteinuric effect of oral paricalcitol in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

Renoprotective role of the vitamin D receptor in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Vitamin D insufficiency and treatment with oral vitamin D3 in northern-dwelling patients with chronic kidney disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3634086

Paricalcitol Versus Ergocalciferol for Secondary Hyperparathyroidism in CKD Stages 3 and 4: A Randomized Controlled Trial

26 October 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0061387

An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease

21 January 2018

1 reference

12 December 2020

Low dose calcitriol versus placebo in patients with predialysis chronic renal failure

1 reference

12 December 2020

Variance imputation for overviews of clinical trials with continuous response

1 reference

12 December 2020

Potential role of active vitamin D in retarding the progression of chronic kidney disease

1 reference

12 December 2020

25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III)

1 reference

12 December 2020

Meta-analysis: vitamin D compounds in chronic kidney disease

1 reference

12 December 2020

New vitamin D analogs

1 reference

12 December 2020

Effect of cholecalciferol on parathyroid hormone and vitamin D levels in chronic kidney disease

1 reference

12 December 2020

Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial

1 reference

12 December 2020

Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0061387

Identifiers

DOI

1 reference

4 August 2017

0 references

1 reference

4 August 2017

1 reference